The addition of sorafenib (Nexavar) to standard chemotherapy or hormone therapy for metastatic breast cancer patients won't extend progression-free survival, according to findings presented at the 2011 European Multidisciplinary Cancer Congress by researchers from Milan's San Raffaele Research Institute.
218 patients took part in the phase II trial (FM-B07-01) of sorafenib, a tyrosine kinase inhibitor with anti-angiogenic and anti-proliferative activity that is currently indicated for renal and hepatocellular carcinoma (kidney and liver cancers).
The primary endpoint was progression-free survival, and findings showed that sorafenib was no better than a placebo when combined with docetaxel (Taxotere) or letrozole (Femara).
Source
Mariani G, et al. "A double-blind, randomized phase IIb study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with docetaxel and/or letrozole in patients with metastatic breast cancer: FM-B07-01 Trial." ECCO-ESMO 2011; Abstract 17LBA.
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
